Gilead buying Cell Design Labs for $567m in further CAR T boost

By Staff Reporter

- Last updated on GMT


Related tags T cell Major histocompatibility complex Protein

Months after jumping into the cell therapy space through the $11.9bn acquisition of Kite, Gilead has agreed to buy CAR T tech firm Cell Design Labs.

In August​, Gilead Sciences acquired Kite for $11.9bn (€10.1bn) and launched itself in the chimeric antigen receptor (CAR) T-cell. Since then, the firm received regulatory approval for its lead product Yescarta (axicabtagene ciloleucel)​ and is now expanding its capabilities in the CAR T space through the acquisition of Cell Design Labs.

Kite Pharma has worked with Cell Design Labs for almost 18 months and integrated its Throttle Switch technology into its CAR T-cell pipeline.

The platform is a precision control tool, enabling a physician to turn CAR T-cells on and off repeatedly, which the firm says allows them to be better tolerated and more effective.

“This is achieved by splitting a standard CAR-T molecule construct into two separate, and inactive, molecular components and cloning these into a patient’s T cell, resulting in the CAR-T cell existing in an ‘off’ state,”​ the firm said.  

“Only in the presence of an FDA-approved small molecule drug will the two components come together – closing the ‘switch’ - into an active state, seeking out and eliminating cancer cells.”

The acquisition will also see Gilead add Cell Design Labs’ synNotch Receptors platform consisting of the reengineering of portions of the naturally occurring Notch receptor making it so a patient’s T cells can be instructed to detect new molecular targets and turn on new genes.

“Bringing our robust technology platforms under the Gilead umbrella, with its outstanding research and development capabilities and commitment to innovation, provides an exciting path forward for the development of the next generation of living therapies for patients with cancer,”​ said Brian Atwood, CEO of Cell Design Labs.

The structured buyout valued at as much as $567m, including the shares of Cell Design Labs held by Kite.

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us


View more